Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Selecta Biosciences, Inc.

http://www.selectabio.com

Latest From Selecta Biosciences, Inc.

Deal Watch: Roche Partners With Dyno On AAV-Delivered Gene Therapies

Also, deals between Boehringer Ingelheim/Oxford BioTherapeutics, Bausch/Eyenovia, Ligand/HitGen, Moderna/Merck & Co., Vincera/Bayer, Genentech/Kineta, Selecta/IGAN, RedHill/AstraZeneca, Urovant/Sunovion, Biogen/Scribe, BridgeBio/Eidos, Elevar/Taiba

Deals Business Strategies

Sobi’s Doptelet Disappoints In Large New Indication

A Phase III trial of Swedish Orphan Biovitrum’s Doptelet in solid tumor cancer patients with chemotherapy-induced thrombocytopenia has failed. The setback could affect the firm’s growth expectations. 

Clinical Trials Companies

Selecta/Sobi Gout Drug Numerically, Not Significantly, Beat Krystexxa

Analysts have mixed opinions about whether a Phase IIb study of SEL-212, which Selecta recently licensed to Sobi, helps the drug’s commercial potential versus Horizon’s Krystexxa.

Clinical Trials Inflammation

Sobi's Revenues Decline 3% In Second Quarter, Signs Of Return To Normality In June

Swedish Orphan Biovitrum’s financial performance in the second quarter was held back by COVID-19 related events, but it has left its financial guidance unchanged for 2020.

Sales & Earnings Blood & Coagulation Disorders
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Nanotechnology, Chips, etc.
UsernamePublicRestriction

Register